Von Hippel-Lindau: How a rare disease illuminates cancer biology

Seminars in Cancer Biology

Volumn 23, Issue 1, 2013, Pages 26-37

  Richard, Stéphane ^a,b   Gardie, Betty ^a,c   Couvé, Sophie ^a   Gad, Sophie ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Angiogenesis; HIF; Renal cell carcinoma; Targeted therapies; Von Hippel Lindau

Indexed keywords

EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR; PAZOPANIB; RANIBIZUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VON HIPPEL LINDAU PROTEIN;

APOPTOSIS; ARTIFICIAL CHROMOSOME; CARCINOGENESIS; CAUSE OF DEATH; CHUVASH POLYCYTHEMIA; CRYOTHERAPY; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; GENE; GENE FUNCTION; GENE MUTATION; GENE TARGETING; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MOLECULAR STABILITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONVIRAL GENE THERAPY; OXYGEN SENSING; PANCREAS CYST; PANCREATIC NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; POLYCYTHEMIA; PROTEIN FUNCTION; RADIOFREQUENCY ABLATION; RETINA MACULA EDEMA; REVIEW; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VHL GENE; VON HIPPEL LINDAU DISEASE;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC ASSOCIATION STUDIES; GERM-LINE MUTATION; HUMANS; NEOPLASMS; RARE DISEASES; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84873084386     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.05.005     Document Type: Review

References (126)

1. Maher E.R., Yates J.R.W., Harries R., Benjamin C., Harris R., Moore A.T., et al. Clinical features and natural history of von Hippel-Lindau disease. Quarterly Journal of Medicine 1990, 77:1151-1163.
2. Lonser R.R., Glenn G.M., Walther M., Chew E.Y., Libutti S.K., Linehan W., et al. von Hippel-Lindau disease. Lancet 2003, 361:2059-2067.
3. Richard S., Graff J., Lindau J., Resche F. Von Hippel-Lindau disease. Lancet 2004, 363:1231-1234.
4. Kaelin W.G. Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer 2002, 2:673-682.
5. Cohen H.T., McGovern F.J. Renal-cell carcinoma. New England Journal of Medicine 2005, 353:2477-2490.
6. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132.
7. Kaelin W.G. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nature Reviews Cancer 2008, 8:865-873.
8. Maher E.R., Neumann H.P.H., Richard S. Von Hippel-Lindau disease: a clinical and scientific review. European Journal of Human Genetics 2011, 19:617-623.
9. Neumann H.P., Eggert H.R., Scheremet R., Schumacher M., Mohadjer M., Wakhloo A.K., et al. Central nervous system lesions in von Hippel-Lindau syndrome. Journal of Neurology, Neurosurgery and Psychiatry 1992, 55:898-901.
10. Richard S., David P., Marsot-Dupuch K., Béroud C., Giraud S., Resche F. Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurgical Review 2000, 23:1-22.
11. Wanebo J.E., Lonser R.R., Glenn G.M., Oldfield E.H. The natural history of central nervous system hemangioblastomas in patients with von Hippel-Lindau disease. Journal of Neurosurgery 2003, 98:82-94.
12. Lonser R.R., Vortmeyer A.O., Butman J.A., Glasker S., Finn M.A., Ammerman J.M., et al. Edema is a precursor to central nervous system peritumoral cyst formation. Annals of Neurology 2005, 58:392-399.
13. Wind J.J., Lonser R.R. Management of von Hippel-Lindau disease-associated CNS lesions. Expert Review of Neurotherapeutics 2011, 11:1433-1441.
14. Webster A.R., Maher E.R., Moore A.T. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Archives of Ophthalmology 1999, 117:371-378.
15. Dollfus H., Massin P., Taupin P., Nemeth C., Amara S., Giraud S., et al. Ocular manifestations in von Hippel-Lindau disease: a clinical and molecular study. Investigative Ophthalmology and Visual Science 2002, 43:3067-3074.
16. Gaudric A., Krivosic V., Duguid G., Massin P., Giraud S., Richard S. Vitreoretinal surgery for severe retinal capillary hemangioblastomas in von Hippel-Lindau disease. Ophthalmology 2011, 118:142-149.
17. Neumann H.P., Bender B.U., Berger D.P., Laubenberger J., Schultze-Seemann W., Wetterauer U., et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. Journal of Urology 1998, 160:1248-1254.
18. Chauveau D., Duvic C., Chrétien Y., Paraf F., Droz D., Melki P., et al. Renal involvement in von Hippel-Lindau disease. Kidney International 1996, 50:944-951.
19. Steinbach F., Novick A.C., Zincke H., Miller D.P., Williams R.D., Lund G., et al. Treatment of renal-cell carcinoma in von Hippel-Lindau disease: a multicenter study. Journal of Urology 1995, 153:1812-1816.
20. Herring J.C., Enquist E.G., Chernoff A., Linehan W.M., Choyke P.L., Walther M.M. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. Journal of Urology 2001, 165:777-781.
21. Rouprêt M., Hopirtean V., Mejean A., Thiounn N., Dufour B., Chrétien Y., et al. Nephron sparing surgery for renal cell carcinoma and von Hippel-Lindau's disease: a single center experience. Journal of Urology 2003, 170:1752-1755. [Erratum in: Journal of Urology 2004;171:811].
22. Duffey B.G., Choyke P.L., Glenn G.M., Grubb R.L., Venzon D., Linehan W.M., et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. Journal of Urology 2004, 172:63-65.
23. Shingleton W.B., Sewell P.E. Percutaneous renal cryoablation of renal tumors in patients with von Hippel-Lindau disease. Journal of Urology 2002, 167:1268-1270.
24. Yang B., Autorino R., Remer E.M., Laydner H.K., Hillyer S., Altunrende F., et al. Probe ablation as salvage therapy for renal tumors in von Hippel-Lindau patients: the Cleveland Clinic experience with 3 years follow-up. Urologic Oncology 2011, [June 30, Epub ahead of print].
25. Joly D., Méjean A., Corréas J.M., Timsit M.O., Deveaux S., Landais P., et al. Progress in nephron-sparing therapy of renal cell carcinoma in von Hippel-Lindau disease. Journal of Urology 2011, 185:2056-2060.
26. Goldfarb D.A., Neumann H.P.H., Penn I., Novick A.C. Results of renal transplantation in patients with renal cell carcinoma in von Hippel-Lindau disease. Transplantation 1997, 64:1726-1729.
27. Richard S., Beigelman C., Duclos J.M., Fendler J.P., Plauchu H., Plouin P.F., et al. Pheochromocytoma as the first manifestation of von Hippel-Lindau disease. Surgery 1994, 116:1076-1081.
28. Walther M.M., Reiter R., Keiser H.R., Choyke P.L., Venzon D., Hurley K., et al. Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. Journal of Urology 1999, 162:659-664.
29. Boedeker C.C., Erlic Z., Richard S., Kontny U., Gimenez-Roqueplo A.P., Cascon A., et al. Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. Journal of Clinical Endocrinology and Metabolism 2009, 94:1938-1944.
30. Eisenhofer G., Walther M.M., Huynh T.T., Li S.T., Bornstein S.R., Vortmeyer A., et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. Journal of Clinical Endocrinology and Metabolism 2001, 86:1999-2008.
31. Eisenhofer G., Lenders J.W., Linehan W.M., Walther M.M., Goldstein D.S., Keiser H.R. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. New England Journal of Medicine 1999, 340:1872-1879.
32. Baghai M., Thompson G.B., Young W.F., Grant C.S., Grant V.V., van Heerden J.A. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Archives of Surgery 2002, 137:682-688.
33. Blansfield J.A., Choyke L., Morita S.Y., Choyke P.L., Pingpank J.F., Alexander H.R., et al. Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007, 142:814-818.
34. Corcos O., Couvelard A., Giraud S., Vullierme M.P., O'Toole D., Rebours V., et al. Endocrine pancreatic tumors in von Hippel-Lindau disease: clinical, histological, and genetic features. Pancreas 2008, 37:85-93.
35. Hammel P.R., Vilgrain V., Terris B., Penfornis F., Sauvanet A., Corréas J.M., et al. Pancreatic involvement in von Hippel-Lindau disease. Gastroenterology 2000, 119:1087-1095.
36. Manski T.J., Heffner D.K., Glenn G.M., Patronas N.J., Pikus A.T., Katz D., et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. The Journal of the American Medical Association 1997, 277:1461-1466.
37. Choo D., Shotland L., Mastroianni M., Glenn G., van Waes C., Linehan W.M., et al. Endolymphatic sac tumors in von Hippel-Lindau disease. Journal of Neurosurgery 2004, 100:480-487.
38. Neumann H.P., Wiestler O.D. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 1991, 337:1052-1054.
39. Maher E.R., Webster A.R., Richards F.M., Green J.S., Crossey P.A., Payne S.J., et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. Journal of Medical Genetics 1996, 33:328-332.
40. Lammens C.R., Bleiker E.M., Verhoef S., Hes F.J., Ausems M.G., Majoor-Krakauer D., et al. Psychosocial impact of von Hippel-Lindau disease: levels and sources of distress. Clinical Genetics 2010, 77:483-491.
41. The VHL handbook: what you need to know about VHL. A reference handbook for people with von Hippel-Lindau disease, their families, and support personnel. VHL Family Alliance ed. 2012; 41 p.
42. Seizinger B.R., Rouleau G.A., Ozelius L.J., Lane A.H., Farmer G.E., Lamiell J.M., et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988, 332:268-269.
43. Latif F., Tory K., Gnarra J., Yao M., Duh F.M., Orcutt M.L., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317-1320.
44. Kim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. Journal of Clinical Oncology 2004, 22:4991-5004.
45. Stebbins C.E., Kaelin W.G., Pavletich N.P. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999, 284:455-461.
46. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271-275.
47. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular Cell 2008, 30:393-402.
48. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., et al. Ubiquitination of HIF requires direct binding to the von Hippel-Lindau protein β domain. Nature Cell Biology 2000, 2:423-427.
49. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292:464-468.
50. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
51. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
52. Singla V., Reiter J.F. The primary cilium as the cell's antenna: signaling at a sensory organelle. Science 2006, 313:629-633.
53. Yolder B.K. Role of primary cilia in the pathogenesis of polycystic kidney disease. Journal of the American Society of Nephrology 2007, 18:1381-1388.
54. Hergovich A., Lisztwan J., Barry R., Ballschmieter P., Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nature Cell Biology 2003, 5:64-70.
55. Esteban M.A., Harten S.K., Tran M.G., Maxwell P.H. Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein. Journal of the American Society of Nephrology 2006, 7:1801-1806.
56. Lutz M.S., Burk R.D. Primary cilium formation requires von Hippel-Lindau gene function in renal-derived cells. Cancer Research 2006, 15(66):6903-6907.
57. Thoma C.R., Matov A., Gutbrodt K.L., Hoerner C.R., Smole Z., Krek W., et al. Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. Journal of Cell Biology 2010, 190:991-1003.
58. Ohh M., Yauch R.L., Lonergan K.M., Whaley J.M., Stemmer-Rachamimov A.O., Louis D.N., et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Molecular Cell 1998, 1:959-968.
59. Kurban G., Duplan E., Ramlal N., Hudon V., Sado Y., Ninomiya Y., et al. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2. Oncogene 2008, 27:1004-1012.
60. Esteban-Barragan M., Avila P., Alvarez-Tejado M., Gutiérrez M.D., García-Pardo A., Sánchez-Madrid F., et al. Role of the von Hippel-Lindau tumor suppressor gene in the formation of β1-integrin fibrillar adhesions. Cancer Research 2002, 62:2929-2936.
61. Lee S., Nakamura E., Yang H., Wei W., Linggi M.S., Sajan M.P., et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005, 8:155-167.
62. Yang H., Minamishima Y.A., Yan Q., Schlisio S., Ebert B.L., Zhang X., et al. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-κB agonist Card9 by CK2. Molecular Cell 2007, 28:15-27.
63. Roe J.S., Kim H., Lee S.M., Kim S.T., Cho E.J., Youn H.D. p53 stabilization and transactivation by a von Hippel-Lindau protein. Molecular Cell 2006, 22:395-405.
64. Roe J.S., Kim H.R., Hwang I.Y., Ha N.C., Kim S.T., Cho E.J., et al. Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation. Cell Cycle 2011, 10:3920-3928.
65. Maher E.R., Yates J.R.W., Ferguson-Smith M.A. Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal-cell carcinoma. Journal of Medical Genetics 1990, 27:311-314.
66. Prowse A.H., Webster A.R., Richards F.M., Richard S., Olschwang S., Resche F., et al. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumours. American Journal of Human Genetics 1997, 60:765-771.
67. Iliopoulos O., Kibel A., Gray S., Kaelin W.G. Tumor suppression by the human von Hippel-Lindau gene product. Nature Medicine 1995, 1:822-826.
68. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002, 1:237-246.
69. Gnarra J., Toty K., Weng Y., Schmidt L., Wei M.H., Li H., et al. Mutations of the VHL tumour suppressor gene in renal carcinomas. Nature Genetics 1994, 7:85-90.
70. Vortmeyer A.O., Gnarra J.R., Emmert-Buck M.R., Katz D., Linehan W.M., Oldfield E.H., et al. Von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Human Pathology 1997, 28:540-543.
71. Park D.M., Zhuang Z., Chen L., Szerlip N., Maric I., Li J., et al. Von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Medicine 2007, 4:e60.
72. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459-468.
73. Montani M., Heinimann K., von Teichman A., Rudolph T., Perren A., Moch H. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. American Journal of Surgical Pathology 2010, 34:806-815.
74. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002, 1:247-255.
75. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Molecular and Cellular Biology 2005, 25:5675-5686.
76. Kondo K., Kim W.Y., Lechpammer M., Kaelin W.G.Jr Inhibition of HIF2α is sufficient to suppress pVHL defective tumor growth. PLoS Biology 2003, 1:E83.
77. Lim W.Y., Kaelin W.G. Role of VHL gene mutation in human cancer. Journal of Clinical Oncology 2004, 22:4991-5004.
78. Banks R.E., Tirukonda P., Taylor C., Hornigold N., Astuti D., Cohen D., et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Research 2006, 66:2000-2011.
79. Beroukhim R., Brunet J.P., Di Napoli A., Mertz K.D., Seeley A., Pires M.M., et al. Patterns of gene expression and copy-number alterations in von Hippel-Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Research 2009, 69:4674-4681.
80. Shuib S., Wei W., Sur H., Morris M.R., McMullan D., Rattenberry E., et al. Copy number profiling in von Hippel-Lindau disease renal cell carcinoma. Genes, Chromosomes and Cancer 2011, 50:479-488.
81. Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
82. Guo G., Gui Y., Gao S., Tang A., Hu X., Huang Y., et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nature Genetics 2011, 44:17-19.
83. Purdue M.P., Johansson M., Zelenika D., Toro J.R., Scelo G., Moore L.E., et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature Genetics 2011, 43:60-65.
84. Schlisio S., Kenchappa R.S., Vredeveld L.C., George R.E., Stewart R., Greulich H., et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes and Development 2008, 22:884-893.
85. Nordstrom-O'Brien M., van der Luijt R.B., van Rooijen E., van den Ouweland A.M., Majoor-Krakauer D.F., Lolkema M.P., et al. Genetic analysis of von Hippel-Lindau disease. Human Mutation 2010, 31:521-527.
86. Zbar B., Kishida T., Chen F., Maher E.R., Richards F.M., Crossey P.A., et al. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe and Japan. Human Mutation 1996, 8:348-357.
87. Olschwang S., Richard S., Boisson C., Giraud S., Laurent-Puig P., Resche F., et al. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Human Mutation 1998, 12:424-430.
88. Stolle C., Glenn G., Zbar B., Humphrey J.S., Choyke P., Walther M., et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation 1998, 12:417-423.
89. Gallou C., Chauveau D., Richard S., Joly D., Giraud S., Olschwang S., et al. Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Human Mutation 2004, 24:215-224.
90. Hes F.J., van der Luijt R.B., Janssen A.L., Zewald R.A., de Jong G.J., Lenders J.W., et al. Frequency of von Hippel-Lindau germline mutations in classic and non-classic von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation dependent probe amplification. Clinical Genetics 2007, 72:122-129.
91. Ong K.R., Woodward E.R., Killick P., Lim C., Macdonald F., Maher E.R. Genotype-phenotype correlations in von Hippel-Lindau disease. Human Mutation 2007, 28:143-149.
92. Béroud C., Joly D., Gallou C., Staroz F., Orfanelli M.T., Junien C. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Research 1998, 26:256-258.
93. Franke G., Bausch B., Hoffmann M.M., Cybulla M., Wilhelm C., Kohlhase J., et al. Alu-Alu recombination underlies the vast majority of large VHL germline deletions: molecular characterization and correlations in VHL patients. Human Mutation 2009, 30:776-886.
94. Sgambati M.T., Stolle C., Choyke P.L., Walther M.M., Zbar B., Linehan W.M., et al. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. American Journal of Human Genetics 2000, 66:84-91.
95. Neumann H.P., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., et al. Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine 2002, 346:1459-1466.
96. Hes F.J., McKee S., Taphoorn M.J., Rehal P., van Der Luijt R.B., McMahon R., et al. Cryptic von Hippel-Lindau disease: germline mutations in patients with haemangioblastoma only. Journal of Medical Genetics 2000, 37:939-943.
97. Brauch H., Kishida T., Glavac D., Chen F., Pausch F., Höfler H., et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Human Genetics 1995, 95:551-556.
98. Clifford S.C., Cockman M.E., Smallwood A.C., Mole D.R., Woodward E.R., Maxwell P.H., et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Human Molecular Genetics 2001, 10:1029-1038.
99. Hoffman M.A., Ohh M., Yang H., Klco J.M., Ivan M., Kaelin W.G. Von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Human Molecular Genetics 2001, 10:1019-1027.
100. Cascón A., Escobar B., Montero-Conde C., Rodríguez-Antona C., Ruiz-Llorente S., Osorio A., et al. Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. Human Mutation 2007, 28:613-621.
101. Mettu P., Agrón E., Samtani S., Chew E.Y., Wong W.T. Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype. Investigative Ophthalmology and Visual Science 2010, 5:4464-4470.
102. Webster A.R., Richards F.M., MacRonald F., Moore A.T., Maher E.R. An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. American Journal of Human Genetics 1998, 63:1025-1035.
103. Ricketts C., Zeegers M.P., Lubinski J., Maher E.R. Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS One 2009, 4:e6037.
104. Ang S.O., Chen H., Hirota K., Gordeuk V.R., Jelinek J., Guan Y., et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genetics 2002, 32:614-621.
105. Liu E., Percy M.J., Amos C.I., Guan Y., Shete S., Stockton D.W., et al. The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood 2004, 103:1937-1940.
106. Russell R.C., Sufan R.I., Zhou B., Heir P., Bunda S., Sybingco S.S., et al. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nature Medicine 2011, 17:845-854.
107. Kaelin W.G. Treatment of kidney cancer; insights provided by the VHL tumor-suppressor protein. Cancer 2009, 115:2262-2272.
108. Linehan W.M., Pinto P.A., Bratslavsky G., Pfaffenroth E., Merino M., Vocke C.D., et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 2009, 115:2252-2261.
109. Albiges L., Salem M., Rini B., Escudier B. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematology/Oncology Clinics of North America 2011, 25:813-833.
110. Jimenez C., Cabanillas M.E., Santarpia L., Jonasch E., Kyle K.L., Lano E.A., et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. Journal of Clinical Endocrinology and Metabolism 2009, 94:386-391.
111. Aiello L.P., George D.J., Cahill M.T., Wong J.S., Cavallerano J., Hannah A.L., et al. Rapid and durable recovery of visual function in a patient with von Hippel-Lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor SU5416. Ophthalmology 2002, 109:1745-1751.
112. Girmens J.F., Erginay A., Massin P., Scigalla P., Gaudric A., Richard S. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. American Journal of Ophthalmology 2003, 136:94-96.
113. Richard S., Croisille L., Yvart J., Casadeval N., Eschwège P., Aghakhani N., et al. Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy. Blood 2002, 99:3851-3853.
114. Madhusudan S., Deplanque G., Braybrooke J.P., Cattell E., Taylor M., Price P., et al. Antiangiogenic therapy for von Hippel-Lindau disease. The Journal of the American Medical Association 2004, 291:943-944.
115. Wong W.T., Liang K.J., Hammel K., Coleman H.R., Chew E.Y. Intravitreal ranibizumab therapy for retinal capillary hemangioblastoma related to von Hippel-Lindau disease. Ophthalmology 2008, 115:1957-1964.
116. Jonash E., McCutcheon I.E., Waguespack S.G., Wen S., Davis D.W., Smith L.A., et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Annals of Oncology 2011, 22:2661-2666.
117. Chen G.J., Karajannis M.A., Newcomb E.W., Zagzag D. Overexpression and activation of epidermal growth factor receptor in hemangioblastomas. Journal of Neuro-Oncology 2010, 99:195-200.
118. Whitesell L., Lin N.U. HSP90 as a platform for the assembly of more effective cancer chemotherapy. Biochimica et Biophysica Acta 2012, 1823:756-766.
119. Kim J.H., Kononenko A., Erliandri I., Kim T.A., Nakano M., Iida Y., et al. Human artificial chromosome (HAC) vector with a conditional centromere for correction of genetic deficiencies in human cells. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:20048-20053.
120. Bommi-Reddy A., Almeciga I., Sawyer J., Geisen C., Li W., Harlow E., et al. Kinase requirements in human cells, III: altered kinase requirements in VHL-/- renal carcinoma cells detected in a pilot synthetic lethal screen. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:16484-16489.
121. Hsu T. Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: insights from model organisms. Oncogene 2012, 31:2247-2257.
122. Haase V.H. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Seminars in Cell and Developmental Biology 2005, 16:564-574.
123. Rankin E.B., Tomaszewski J.E., Haase V.H. Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor. Cancer Research 2006, 66:2576-2583.
124. Frew I.J., Thoma C.R., Georgiev S., Minola A., Hitz M., Montani M., et al. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO Journal 2008, 27:1747-1757.
125. Fu L., Wang G., Shevchuk M.M., Nanus D.M., Gudas L.J. Generation of a mouse model of von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1α. Cancer Research 2011, 71:6848-6856.
126. Shen H.C., Adem A., Ylaya K., Wilson A., He M., Lorang D., et al. Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS One 2009, 4:e4897.